Clinical Trials Logo

Clinical Trial Summary

This ia a multicenter, Single-Arm, Open-Label Phase I Clinical Study Evaluating the Safety and Tolerability of Pelareorep Combined with Paclitaxel Injection and the Intracorporal Process of Pelareorep in Chinese Patients with Advanced or Metastatic Breast Cancer.


Clinical Trial Description

This study will enroll patients with advanced or metastatic breast cancer to assess the safety and tolerability of Pelareorep at 1.5×10^10, 3.0×10^10, 4.5×10^10 (TCID50) combined with paclitaxel to fix the MTD or RP2D. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05519059
Study type Interventional
Source Adlai Nortye Biopharma Co., Ltd.
Contact
Status Completed
Phase Phase 1
Start date October 11, 2021
Completion date May 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT00748553 - A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer Phase 1/Phase 2
Recruiting NCT05187832 - A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer Phase 1
Completed NCT01625286 - Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients Phase 1/Phase 2
Terminated NCT05932667 - Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT04742153 - A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC) Phase 2
Not yet recruiting NCT06201234 - Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer Phase 2
Completed NCT02154776 - Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. Phase 1
Active, not recruiting NCT04494425 - Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Phase 3
Completed NCT03767335 - MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer Phase 1
Recruiting NCT06105632 - A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment Phase 3
Completed NCT01676753 - Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer Phase 1
Active, not recruiting NCT01226316 - Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules Phase 1